Good MorningA much-needed market correction is underway and may not end soon. The sell-off was sparked by a sell-the-news event that has yet to play out. The news was the June CPI report, which was affirmed by the PCE price index; consumer inflation is falling closer to the FOMC's target of 2%, paving the path toward an interest rate cut. The significant detail is the interest rate cut, a move that will signal the easing of economic headwinds and a pivot for the market. That pivot will be into small and mid-cap names, driven by the expectation improving business conditions will drive growth and profits.
This week's risk is the FOMC. The FOMC is meeting on Tuesday and Wednesday and will release a fresh policy statement on Wednesday. The market is pricing in a rate cut for August and a high probability for a second in September. Still, the FOMC may hesitate to commit, inducing volatility in the market. The takeaway is that underlying economic conditions and outlook remain bullish; a stock market correction should result in a buy-the-dip opportunity and fresh all-time highs later this year. Featured: Beginner Crash Course In Options Trading (Unstoppable Prosperity) 
|
Markets | | |
Some names in the retail and apparel sectors have made a splash in investors’ monitors in recent weeks, even months. Unfortunately, the attention is founded on seriously bearish price action, like the fact that shares of Lululemon Athletica Inc. (NASDAQ: LULU) are now trading at only 48% of ... Read the Full Story |
|
From Our PartnersThere’s a free dividend workshop that shows how anyone can build the ultimate dividend workshop in 3 basic steps?
PLUS: You’ll get the names and tickers of the Best Dividend Stocks for FREE…
This way, by the time you finish the workshop you’ll be fully equipped with the knowledge to start unlocking dividend checks for yourself… Over and over again. | | | | Click here and I’ll show you how to build the ultimate dividend portfolio. |
|
Markets | | | The earnings reports from Alphabet Inc. (NASDAQ: GOOGL) and Tesla Inc. (NASDAQ: TSLA) led technology stocks lower for the week. Some analysts are warning that the price action is due to an artificial intelligence (AI) bubble, but there could be other factors at play.
First, the second h... Read the Full Story |
|
Markets | | | The world of cryptocurrency is still a developing thesis, with some raging bulls on every coin out there and others calling the asset class a complete scam and Ponzi scheme. Whether one side is right or wrong is up for debate, but one thing remains true: investor and trader psychology and behavior.
... Read the Full Story |
|
|
Stocks | | | A widespread rally swept Wall Street Friday, lifting far-reaching corners, to close a tumultuous week where stocks that had been left behind for much of this year’s record-setting run wrested the spotlight back from the market’s biggest stars.The S&P 500 jumped 1.1% for its best day in seven wee... Read the Full Story |
|
Markets | | | Owning stock gives investors a one-for-one behavior in the underlying stock, and that’s good enough when there is a longer timeframe. But it won’t cut it for big traders looking to quickly get a hit-and-run stock move.
That’s where stock options come in. They allow investors to ac... Read the Full Story |
|
|
Markets | | | Asian shares mostly declined in cautious trading Tuesday ahead of central bank meetings around the world. The Federal Reserve, the Bank of England and the Bank of Japan are holding monetary policy meetings this week. Japan's benchmark Nikkei 225 lost 0.5% in morning trading to 38,268.72. Australia's... Read the Full Story |
|
Markets | | |
3M’s (NYSE: MMM) rebound is gaining momentum because of surprisingly good results. Today’s story is that repositioning efforts are taking hold and driving improved profitability while litigation risks dwindle. The takeaways from the Q2 report include better-than-expected top and bottom... Read the Full Story |
|
Markets | | | Two years after launching an aggressive fight against inflation and one year after leaving its benchmark interest rate at a near-quarter-century high, the Federal Reserve is expected to signal this week that it will likely reduce borrowing costs as soon as September Read the Full Story |
|
Markets | | | All of a sudden it's Kamala Harris ' economy — a major opportunity as well as a possible risk for the likely Democratic presidential nominee.Shortly after President Joe Biden left the race a week ago, Harris began to craft her own narrative around the economy by putting an emphasis on ending child p... Read the Full Story |
|
Markets | | | The Federal Reserve’s favored inflation measure remained low last month, bolstering evidence that price pressures are steadily cooling and setting the stage for the Fed to begin cutting interest rates in September Read the Full Story |
|
Monday's Early Bird Stock Of The Day Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California. | Should I Buy Edwards Lifesciences Stock? EW Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Edwards Lifesciences was last updated on Wednesday, June 04, 2025 at 7:05 PM.
Edwards Lifesciences Bull Case -
The current stock price is around $78, which is relatively stable compared to its 12-month high of $95.25, indicating potential for growth.
-
Edwards Lifesciences Co. reported a strong earnings per share of $0.64, surpassing analyst expectations, which reflects solid financial performance.
-
The company has shown a year-over-year revenue increase of 6.2%, suggesting a positive growth trajectory in its business operations.
-
With a market capitalization of approximately $45.81 billion, Edwards Lifesciences Co. is a significant player in the medical research sector, providing stability and investor confidence.
-
The company maintains a low debt-to-equity ratio of 0.06, indicating a strong balance sheet and lower financial risk, which is attractive for long-term investors.
Edwards Lifesciences Bear Case -
Insider selling has been notable, with executives selling over 56,000 shares recently, which may signal a lack of confidence in the stock's short-term performance.
-
The average analyst rating for Edwards Lifesciences Co. is "Hold," suggesting that many experts do not see immediate upside potential.
-
The price-to-earnings (P/E) ratio of 11.20, while not excessively high, may indicate that the stock is fairly valued, limiting potential for significant price appreciation.
-
Some analysts have downgraded their ratings, with one firm moving from a "hold" to a "strong sell," which could reflect concerns about future performance.
-
The price-to-earnings-growth (PEG) ratio of 4.82 suggests that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
| | View Today's Stock Pick |
|
